A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE￠) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

F.Cardoso; Azambuja; C.Bernard; L.Dirix; D.De Becker; S.Bartholomeus; V.DHondt; H.van de Velde; M.Piccart; A.Awada

首页> 外文期刊>European Journal of Cancer Supplements >A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE￠) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

【24h】

A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE￠) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

机译：蛋白酶体抑制剂PS-341（VELCADE ￠）与两种方案的曲妥珠单抗联合进行的I期，开放标签，剂量递增的研究，用于过度表达HER-的晚期乳腺癌（ABC）患者2

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第2期|共1页
作者
F.Cardoso; Azambuja; C.Bernard; L.Dirix; D.De Becker; S.Bartholomeus; V.DHondt; H.van de Velde; M.Piccart; A.Awada;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade?), in combination with paclitaxel and carboplatin in patients with advanced malignancies [J] . Cynthia Ma, Sumithra J. Mandrekar, Steven R. Alberts, Cancer Chemotherapy and Pharmacology . 2007,第2期

机译：蛋白酶体抑制剂硼替佐米（PS-341，Velcade？）与紫杉醇和卡铂联合用于晚期恶性肿瘤患者的I期和药理学研究
2. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). [J] . Li T, Ho L, Piperdi B, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2010,第1期

机译：蛋白酶体抑制剂硼替佐米（PS-341，Velcade）在未经化疗的晚期非小细胞肺癌（NSCLC）患者中进行的II期研究。
3. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. [J] . Thomas A, Trarbach T, Bartel C, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第4期

机译：IB期开放标签剂量递增研究对晚期大肠癌患者的口服血管生成抑制剂PTK787 / ZK 222584（PTK / ZK）联合FOLFOX4化疗。
4. Nonclinical Discovery and Development of Bortezomib (PS-341, VELCADE~(R)) a Proteasome Inhibitor for the Treatment of Cancer [C] . Bouchard PR, Juedes M, Nix D, Annual Meeting of the American Society for Veterinary Clinical Pathology . 2004

机译：Bortezomib（PS-341，Velcade〜（R）的非临床发现和发展）一种治疗癌症的蛋白酶体抑制剂
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Phase II 2-arm trial of the proteasome inhibitor PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group [O] . Jill Gilbert, Ju Whei Lee, Athanassios Argiris, -1

机译：II 2-ARM试验蛋白酶体抑制剂PS-341（Bortezomib）与Irinotecan或PS-341组合然后在患有头部局部复发或转移鳞状细胞癌的患者的进展时加入伊立替康。颈部（E1304）：东方合作肿瘤组的试验
7. A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes [O] . Christopher Mansbridge, Peter Simmonds, Nicholas Murray, 2020

机译：与吉西他滨组合的Carboplatin相结合的2个开放标签研究作为患有临时或转移性乳腺癌的患者的剂量密集的时间表，这些时间表抵抗蒽氟胺和紫杉烷
8. Phase II Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab [R] . Disis, M. L. 2010

机译：对接受曲妥珠单抗的IV期HER2阳性乳腺癌患者施用HER-2 / neu胞内域肽基疫苗的II期研究

A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE￠) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

著录项

相似文献

相关主题

期刊订阅